NHS-DTP | 123861-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: NHS-DTP
• 英文别名: SPDP；(2,5-Dioxopyrrolidin-1-yl) 3-(phenyldisulfanyl)propanoate
• CAS: 123861-58-5
• 化学式: C₁₃H₁₃NO₄S₂
• 分子量: 311.383
• InChiKey: QSRARBOVLIVRJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  NHS-DTP 在 三乙胺 、 N,N'-二环己基碳二亚胺 、 zinc(II) chloride 作用下， 以 乙二醇二甲醚 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2R)-2-[methyl-[3-(phenyldisulfanyl)propanoyl]amino]propanoate
  参考文献：
  名称：

  Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer

  摘要：

  Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

  DOI：

  10.1021/jm060319f
• 作为产物：
  描述：

  二苯二硫醚 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 反应 22.0h， 生成 NHS-DTP
  参考文献：
  名称：

  Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer

  摘要：

  Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

  DOI：

  10.1021/jm060319f

文献信息

• [EN] COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INDUCTION D'UNE TOLÉRANCE IMMUNITAIRE
  申请人：UNIV CHICAGO

  公开号：WO2018232176A1

  公开（公告）日：2018-12-20

  Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.

  本公开提供的一些实施例涉及承载期望产生耐受性的抗原的组成物，该抗原通过与靶向部分耦合、结合或以其他方式连接，该靶向部分配置为将组成物导向受试者的肝脏。在一些实施例中，通过聚合物连接剂将抗原与靶向部分连接。在一些实施例中，聚合物连接剂配置为在体内释放抗原。还提供了使用这些组成物来减少和/或预防对感兴趣抗原的未期望免疫反应的方法。
• KIDNEY-TARGETING DRUG DELIVERY CARRIER
  申请人：Kyoto Pharmaceutical University

  公开号：EP3650484A1

  公开（公告）日：2020-05-13

  The present invention relates to a compound having a macromolecular carrier having a plurality of terminal groups, wherein the carbonyl group of serine is linked by a peptide bond or an ester bond directly or via a linker to the terminal groups, a carrier for drug delivery composed of the compound, and a medicament for preventing or treating renal diseases, containing the carrier for drug delivery and a drug bonded to the carrier directly or via a linker or encapsulated therein. According to the present invention, a carrier for drug delivery that is selectively accumulated in kidney in vivo can be provided.

  本发明涉及一种具有大分子载体的化合物，该载体具有多个末端基团，其中丝氨酸的羰基通过肽键或酯键直接或通过连接体与末端基团相连；一种由该化合物组成的给药载体；以及一种用于预防或治疗肾脏疾病的药物，该药物含有该给药载体和直接或通过连接体与载体相连或封装在载体中的药物。根据本发明，可以提供一种在体内选择性蓄积于肾脏的给药载体。
• Compositions and methods for inducing immune tolerance
  申请人：The University of Chicago

  公开号：US11253579B2

  公开（公告）日：2022-02-22

  Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.

  本公开提供的几个实施方案涉及携带抗原的组合物，抗原与靶向分子偶联、结合或以其他方式连接，靶向分子被配置为将组合物导向受试者的肝脏。在几个实施方案中，抗原通过聚合连接体与靶向分子连接。在几个实施方案中，聚合连接体被配置为在体内释放抗原。此外，还提供了使用组合物减少和/或预防针对相关抗原的不必要免疫反应的方法。
• COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
  申请人：The University of Chicago

  公开号：US20220211826A1

  公开（公告）日：2022-07-07

  Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.
• US5239062A
  申请人：——

  公开号：US5239062A

  公开（公告）日：1993-08-24